Acute thrombocytopenia and fibrinogen reduction occurring after nintedanib treatment for immune checkpoint inhibitor-related pneumonia: a case report
BackgroundNintedanib, a small molecule multi-target tyrosine kinase inhibitor, can block the fibrosis process and slow disease progression. Acute thrombocytopenia and fibrinogen reduction caused by nintedanib is a rare clinical event, with few studies reported.Case presentationWe report the case of...
Saved in:
| Main Authors: | Jian Zheng, Nan Zhou, Dexiang Pang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1561440/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Can Pirfenidone and Nintedanib Be Alternative Treatment Options for Radiation Pneumonitis?
by: Hikmet COBAN, et al.
Published: (2025-06-01) -
Predictive value of machine learning for radiation pneumonitis and checkpoint inhibitor pneumonitis in lung cancer patients: a systematic review and meta-analysis
by: Shenghan Wang, et al.
Published: (2025-07-01) -
A Systematic Review of Pneumonitis Following Treatment with Immune Checkpoint Inhibitors and Radiotherapy
by: Melina Yerolatsite, et al.
Published: (2025-04-01) -
Managing Immune Checkpoint Inhibitor Pneumonitis in the ICU
by: Kristina Montemayor, MD, MHS, et al.
Published: (2025-03-01) -
Interactions between interstitial lung abnormalities and immune checkpoint inhibitor therapy in non-small cell lung cancer: A review of current understanding and future directions
by: Ryota Kikuchi, et al.
Published: (2025-12-01)